greeksoup/ stock research

AbbVie (ABBV) Q4 FY2025 earnings: revenue $16.6 billion, up 10.0% on the year

AbbVie Inc. (ABBV) reported revenue of $16.6 billion for Q4 FY2025, the quarter ended 31 December 2025, up 10.0% on the same quarter a year earlier. Net income was $1.8 billion, and diluted earnings per share $1.02. The figures are the company's own, from the 10-K it filed with the SEC on 20 February 2026.

Revenue
$16.6 billion
+10.0% on the year · +5.3% on the quarter
Q1 FY2024Q4 FY2025
Operating margin
27.3%
-9.9% a year earlier
Q1 FY2024Q4 FY2025
Net income
$1.8 billion
+876.3% on the quarter
Q1 FY2024Q4 FY2025
Diluted EPS
$1.02
+920.0% on the quarter
Q1 FY2024Q4 FY2025

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ4 FY2025Q3 FY2025Q4 FY2024On the quarterOn the yearLast 8 quarters
Revenue16,61815,77615,102+5.3%+10.0%
Cost of revenue4,5525,3044,396-14.2%+3.5%
Gross profit12,06610,47210,706+15.2%+12.7%
Gross margin72.6%66.4%70.9%
Research and development2,5792,3196,774+11.2%-61.9%
Selling, general and administrative3,8953,5693,855+9.1%+1.0%
Operating income4,5441,904-1,490+138.7%
Operating margin27.3%12.1%-9.9%
Interest expense714739702-3.4%+1.7%
Pre-tax income2,668714-2,269+273.7%
Income tax853526-2,246+62.2%
Effective tax rate32.0%73.7%n/a
Net income1,816186-22.0+876.3%
Net margin10.9%1.2%-0.1%
Diluted EPS$1.02$0.10-$0.02+920.0%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ4 FY2025Q3 FY2025Q4 FY2024On the quarterOn the yearLast 8 quarters
Operating cash flow5,2187,0247,048-25.7%-26.0%
Capital expenditure329381291-13.6%+13.1%
Free cash flow4,8896,6436,757-26.4%-27.6%
Free cash flow margin29.4%42.1%44.7%
Cash from investing-1,463-3,264-1,874
Cash from financing-4,166-4,590-6,861
Depreciation and amortisation1,9222,0922,137-8.1%-10.1%
Share-based compensation157209164-24.9%-4.3%
Buybacks3.04.0358-25.0%-99.2%
Dividends paid2,9112,9112,7520.0%+5.8%
Dividend per share$1.73$1.64$1.64+5.5%+5.5%
Diluted shares, weightedn/a1,772mn/a
Shares outstanding at period end1,768m1,767m1,765m+0.0%+0.2%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ4 FY2025Q3 FY2025Q4 FY2024On the quarterOn the yearLast 8 quarters
Shareholders' equity-3,270-2,6423,325
Non-controlling interest42.043.039.0-2.3%+7.7%
Short-term borrowingsn/an/a0.0
Debt67,49668,74366,841-1.8%+1.0%
Operating lease liabilities689n/a697-1.1%
Finance lease liabilities22.0n/a23.0-4.3%
Other liabilities68,98167,75464,236+1.8%+7.4%
Total liabilities and equity133,960133,898135,161+0.0%-0.9%
Fixed assets5,6285,4835,134+2.6%+9.6%
Goodwill35,64035,62634,956+0.0%+2.0%
Intangible assets52,64154,31560,068-3.1%-12.4%
Investments296333310-11.1%-4.5%
Cash and equivalents5,2295,6295,524-7.1%-5.3%
Receivables12,58912,76910,919-1.4%+15.3%
Inventory4,9514,9384,181+0.3%+18.4%
Other assets16,98614,80514,069+14.7%+20.7%
Total assets133,960133,898135,161+0.0%-0.9%

Questions

What was AbbVie's revenue in Q4 FY2025?

AbbVie (ABBV) reported revenue of $16.6 billion for Q4 FY2025, the quarter ended 31 December 2025, up 10.0% on the same quarter a year earlier.

How much did AbbVie earn in Q4 FY2025?

Net income for Q4 FY2025 was $1.8 billion, and diluted earnings per share $1.02.

When did AbbVie report Q4 FY2025 results?

AbbVie filed its 10-K for the quarter ended 31 December 2025 with the SEC on 20 February 2026.

Quarterly results, the last 20 quarters

Q4 FY2021Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue14,88613,53814,58314,81215,12112,22513,86513,92714,30112,31014,46214,46015,10213,34315,42315,77616,61815,00216,99017,404
Cost of revenue4,3204,0524,1705,0224,1703,9864,2406,4855,7044,0944,2024,2124,3964,0024,3465,3044,5524,2184,2914,285
Gross profit10,5669,48610,4139,79010,9518,2399,6257,4428,5978,21610,26010,24810,7069,34111,07710,47212,06610,78412,69913,119
Gross margin71%70%71%66%72%67%69%53%60%67%71%71%71%70%72%66%73%72%75%75%
R&D1,8271,4971,6091,6141,7902,2921,7331,7231,9271,9391,9482,1306,7742,0672,1312,3192,5792,4722,3442,567
SG&A3,2603,1275,4123,3043,4173,0393,2683,3723,1933,3153,3774,2053,8553,2933,2533,5693,8953,5783,6324,087
Operating income5,0744,7173,2954,6035,5022,7684,5132,2813,1952,7983,9983,831-1,4903,7334,8941,9044,5443,9906,4326,267
Operating margin34%35%23%31%36%23%33%16%22%23%28%26%-10%28%32%12%27%27%38%36%
Interest expense580548556560566553552555564660726720702700740739714717746802
Pre-tax income4,2714,9291,1834,4002,9654752,6101,9531,2121,7552,1462,084-2,2691,6611,5547142,6681,0394,2784,829
Tax rate5%9%22%10%17%49%22%9%32%22%36%25%n/a22%39%74%32%33%15%13%
Net income4,0444,4909243,9492,4732392,0241,7788221,3691,3701,561-22.01,2869381861,8166953,6134,218
Net margin27%33%6%27%16%2%15%13%6%11%9%11%-0%10%6%1%11%5%21%24%
Diluted EPS$2.26$2.51$0.51$2.21$1.38$0.13$1.14$1.00$0.46$0.77$0.77$0.88-$0.02$0.72$0.52$0.10$1.02$0.39$2.03$2.37
Operating cash flow5,0754,9085,0057,6027,4284,1936,3197,5744,7534,0402,2715,4477,0481,6355,1537,0245,2183,8293,4367,606
Capital expenditure187162143177213175178219205193241249291235269381329265322301
Free cash flow4,8884,7464,8627,4257,2154,0186,1417,3554,5483,8472,0305,1986,7571,4004,8846,6434,8893,5643,1147,305
Buybacks1311,4709.04.04.01,95510.04.03.01,3249.017.035896112.04.03.01,4899.05.0
Dividends paid2,3142,5262,5072,5042,5062,6612,6252,6272,6262,7722,7502,7512,7522,9252,9102,9112,9113,0863,0703,071
Shares outstanding1,769m1,767m1,768m1,768m1,769m1,764m1,765m1,766m1,766m1,766m1,766m1,767m1,765m1,766m1,767m1,767m1,768m1,767m1,767m1,768m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 31 December 2025, filed 20 February 2026: the filing.